Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: Results of a new treatment paradigm

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 5, 2004, Pages 1411-1417

  Arnold, Susanne M ^a,c   Regine, William F ^b   Ahmed, Mansoor M ^a   Valentino, Joseph ^a   Spring, Paul ^a   Kudrimoti, Mahesh ^a   Kenady, Daniel ^a   Desimone, Philip ^a   Mohiuddin, Mohammed ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Chemotherapy; Induction; Low dose; Radiotherapy

Indexed keywords

CELLS; CHEMOTHERAPY; DISEASE CONTROL; FRACTIONATION; PATIENT MONITORING; RADIOTHERAPY;

CARBOPLATIN; NEUTROPENIA;

TUMORS;

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DISEASE COURSE; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DYSURIA; ENDOSCOPY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HUMAN; INFECTION COMPLICATION; LUNG TOXICITY; LYMPH NODE CELL; MALE; MOTOR NEURON DISEASE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RADIODIAGNOSIS; SKIN ALLERGY; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 1842476896     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.09.019     Document Type: Article

References (38)

1. Kies M.S., Bennett C.L., Vokes E.E. Locally advanced head and neck cancer. Curr Treat Options Oncol. 2:2001;7-13.
2. Schilsky R.L. Biochemical pharmacology of chemotherapeutic drugs used as radiation enhancers. Semin Oncol. 19:(4 Suppl. 11):1992;2-7.
3. Milas L., Milas M.M., Mason K.A. Combination of taxanes with radiation Preclinical studies. Semin Radiat Oncol. 9(2 Suppl. 1):1999;12-26.
4. Liebmann J., Cook J.A., Fisher J., et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 86:1994;441-446.
5. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 91:1999;2081-2086.
6. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancers. N Engl J Med. 338:1998;1798-1804.
7. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer A randomized multicenter study. J Clin Oncol. 16:1998;1318-1324.
8. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 21:2003;92-98.
9. Vokes E., Kies M., Haraf D., et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 18:2000;1652-1661.
10. Kies M., Haraf D.J., Rosen F., et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 19:2001;1961-1969.
11. Rosen F.R., Haraf D.J., Kies M., et al. Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil and hydroxyurea with concomitant twice daily hyperfractionated radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 9:2003;1689-1697.
12. Pignon J.P., Bourhis J., Domenge C., et al. Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC) Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma Three meta-analyses of updated individual data. Lancet. 355:2000;949-955.
13. Vokes E.E., Mick R., Lester E.P., et al. Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer Results from a single institution. J Clin Oncol. 9:1991;1376-1384.
14. Domenge C., Hill C., LeFebvre J.L., et al. French Group d'Etude des Tumeurs de la Tete et du Gou (GETTEG). Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinomas. Br J Cancer. 83:2000;1594-1598.
15. Vokes E., Stenson K., Rosen F., et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil and hydroxyurea chemoradiotherapy Curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 21:2003;320-326.
16. Licitra L., Grandi C., Guzzo M., et al. Primary chemotherapy in resectable oral cavity squamous cell carcinoma A randomized controlled trial. J Clin Oncol. 21:2003;327-333.
17. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy and radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 324:1991;1685-1690.
18. Vokes E.E., Kies M., Haraf D.J., et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer Impact on the natural history of the disease. J Clin Oncol. 13:1995;876-883.
19. LeFebvre J.L., Chevalier D., Luboinski B., et al. EORTC Head and Neck Cancer Cooperative Group. Larynx preservation in pyriform sinus cancer Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst. 88:1996;890-899.
20. Hitt R., Paz-Ares L., Hidlago M., et al. Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer. Semin Oncol. 24:(6 Suppl. 19):1997;S19-S24.
21. Colevas A.D., Busse P.M., Norris C.M., et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and leucovorin for squamous cell carcinoma of the head and neck A phase I/II trial. J Clin Oncol. 16:1998;1331-1339.
22. Dunphy F.R., Dunleavy T.L., Harrison B.R., et al. Induction paclitaxel and carboplatin for patients with head and neck carcinoma Analysis of 62 patients treated between 1994 and 1999. Cancer. 91:2001;940-948.
23. Machtay M.M., Rosenthal D.I., Hershock D., et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma A University of Pennsylvania phase II trial. J Clin Oncol. 20:2002;3964-3971.
24. Bouillet T., Morere J.F., Depreaux G., et al. Phase II study of paclitaxel (P) twice a week as a radiosensitizer, after paclitaxel-carboplatin (C) induction in stage III-IV head and neck carcinoma. [Abstract] Proc Am Soc Clin Oncol. 18:1999;403a.
25. Joiner M.C., Marples B., Lambin P., et al. Low-dose hypersensitivity Current status and possible mechanisms. Int J Radiat Oncol Biol Phys. 49:2001;379-389.
26. Marples B., Cann N.E., Mitchell C.R., et al. Evidence for the involvement of DNA-dependent protein kinase in the phenomena of low dose hyper-radiosensitivity and increased radioresistance. Int J Radiat Biol. 78:2002;1139-1147.
27. Dey S., Spring P., Arnold S.M., et al. Low dose fractionated radiation potentiates the effects of paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res. 9:2003;1557-1565.
28. Arnold S.M., Regine W., Valentino J., et al. Use of low-dose fractionated radiation as a chemosensitizer of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck - Results of a new treatment paradigm. [Abstract] Proc Am Soc Clin Oncol. 21:2002;231a. Abstr. #921.
29. National Cancer Institute Common Toxicity Criteria. Http://ctep. cancer. gov/forms/CTCv20_4-30-992.pdf.
30. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 10:1989;1-10.
31. Regine W.F., Valentino J., Arnold S.M., et al. High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 19:2001;3333-3339.
32. Posner M.R., Glisson B., Frenette G., et al. Multicenter phase I-II trial of docetaxel, cisplatin and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 19:2001;1096-1104.
33. Hitt R., Paz-Ares L., Brandariz A., et al. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck Long-term results of a phase II trial. Ann Oncol. 13:2002;1665-1673.
34. Liengswangwong V., Bonner J.A., Shaw E.G., et al. Limited-stage small-cell lung cancer Patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol. 12:1994;496-502.
35. Short S., Mayes C., Woodcock M., et al. Low dose hypersensitivity in the T98G human glioblastoma cell line. Int J Radiat Biol. 75:1999;847-855.
36. Shajahan S., Dey S., Arnold S.A., et al. Effects of radiation and chemotherapy on multidrug resistance gene expression in oral cavity cancer. [Abstract] Proc Am Assoc Can Res. 44:2003;1412. (Abstr. #6160).
37. Spring P.S., Arnold S., Dimova N., et al. Low-dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of the head and neck. Cell Cycle. 2004;. in press.
38. Belani C.P., Barstis J., Perry M.C. Multi-center randomized trial for stage IIIB or IV non-small cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 21:2003;2933-2939.